Bladder Cancer - Management of NMI and Muscle-Invasive Cancer 2017
DOI: 10.5772/67309
|View full text |Cite
|
Sign up to set email alerts
|

Bladder Cancer Markers and Recent Innovations

Abstract: Bladder cancer (urothelial carcinoma) is the most common tumor of the urinary tract. It occurs more frequently among men about 65 years old on average. Two forms of the tumor are known: a non-muscle-invasive one and a muscle-invasive one. The latter turns out to be very aggressive with a survival of 5 years average. The non-muscle-invasive form frequently recurs (60-70%) and in 15% of cases, it progresses into the invasive form. The diagnosis is made mainly by cystoscopy and urine cytology. A high number of re… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2019
2019
2021
2021

Publication Types

Select...
1
1

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 127 publications
(195 reference statements)
0
1
0
Order By: Relevance
“…At present, there are several commercial assays for bladder cancer diagnosis based on immunoassays, but they have high variability of sensitivity and specificity. In addition, in most of them the false-positive rate is quite high, they require tedious/laborious assay procedures, are time consuming, expensive and need specialized personnel [9,10]. To this aim, the development of portable, low cost, multiplexed and easy to use devices that, within minutes, can detect cancer biomarkers directly from biofluids is instrumental.…”
Section: Introductionmentioning
confidence: 99%
“…At present, there are several commercial assays for bladder cancer diagnosis based on immunoassays, but they have high variability of sensitivity and specificity. In addition, in most of them the false-positive rate is quite high, they require tedious/laborious assay procedures, are time consuming, expensive and need specialized personnel [9,10]. To this aim, the development of portable, low cost, multiplexed and easy to use devices that, within minutes, can detect cancer biomarkers directly from biofluids is instrumental.…”
Section: Introductionmentioning
confidence: 99%